Brian G.M. Durie, MD

In Newly Diagnosed Myeloma Patients, Triplets Preferred

February 2016, Vol. 5, No. 1 - ASH 2015, ASH Highlights

While the cost of treating newly diagnosed patients is greatly increased with the use of 3 drugs, doublets should not be considered adequate, and triplets should be the standard of care, according to results from a randomized trial.The use of triplets—including a proteasome inhibitor, immunomodulatory drug (IMiD), and steroid—has been [ Read More ]